Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00948558
Other study ID # KY2009-108
Secondary ID
Status Recruiting
Phase N/A
First received July 28, 2009
Last updated August 4, 2009
Start date March 2009
Est. completion date September 2011

Study information

Verified date August 2009
Source Huashan Hospital
Contact Feng Ding, Professor
Phone 86-02152888135
Email ding_feng@hotmail.com
Is FDA regulated No
Health authority China:Ehtics Committee
Study type Observational

Clinical Trial Summary

1. To compare the differences of citrate pharmacokinetics in healthy individuals and critically ill patients as well as the influential factors.

2. To validate a pharmacokinetic model which has been established in a formal paper.

3. To create a safe and effective RCA-CRRT protocol.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date September 2011
Est. primary completion date December 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- healthy individuals, none-pregnant

- diagnosed with acute renal failure according to RIFLE criteria

- ARF with hepatic insufficiency

- ARF with MODS or sepsis

- within informed consent

Exclusion Criteria:

- used drugs with citrate within one week

- infused with blood,plasma or platelet or undergone plasma exchange therapy within 48 hours

- serious alkalosis with PH>7.55

- serious lactic acidosis

- not in resuscitation state

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
China Huashan hospital Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Huashan Hospital Shanghai Scientific and technology committe

Country where clinical trial is conducted

China, 

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3